Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Driessen

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 5, 2014
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registryJ M P A van den Reek, M Tummers, J Zweegers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 10, 2017
The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registryJ M P A van den Reek, M M B Seyger, P P M van Lümig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 18, 2026
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short versionAlexander Nast, Bassel H Al Wattar, Marie Beylot Barry, et al.
Dermatology (Basel, Switzerland)|December 8, 2022
Which Health-Related Quality of Life Items Most Affect Acne Patients?Pavel V Chernyshov, Francesca Sampogna, Christos C Zouboulis, et al.
The British Journal of Dermatology|March 19, 2016
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registryJ Zweegers, J M P A van den Reek, P C M van de Kerkhof, et al.
The British Journal of Dermatology|September 1, 2016
Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registryJ Zweegers, J M M Groenewoud, J M P A van den Reek, et al.
The British Journal of Dermatology|July 26, 2016
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohortJ Zweegers, B Roosenboom, P C M van de Kerkhof, et al.
The British Journal of Dermatology|May 9, 2014
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE networkJ M P A van den Reek, J Zweegers, W Kievit, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 5, 2014
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registryJ M P A van den Reek, M Tummers, J Zweegers, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 10, 2017
The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registryJ M P A van den Reek, M M B Seyger, P P M van Lümig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 18, 2026
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short versionAlexander Nast, Bassel H Al Wattar, Marie Beylot Barry, et al.
Dermatology (Basel, Switzerland)|December 8, 2022
Which Health-Related Quality of Life Items Most Affect Acne Patients?Pavel V Chernyshov, Francesca Sampogna, Christos C Zouboulis, et al.
The British Journal of Dermatology|March 19, 2016
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registryJ Zweegers, J M P A van den Reek, P C M van de Kerkhof, et al.
The British Journal of Dermatology|September 1, 2016
Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registryJ Zweegers, J M M Groenewoud, J M P A van den Reek, et al.
The British Journal of Dermatology|July 26, 2016
Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohortJ Zweegers, B Roosenboom, P C M van de Kerkhof, et al.
The British Journal of Dermatology|May 9, 2014
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE networkJ M P A van den Reek, J Zweegers, W Kievit, et al.
Pageof 10